Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Real-time RT-PCR assay monitors DEK-CAN fusion transcripts in AML
December 28th, 2004
A real-time RT-PCR assay monitors DEK-CAN fusion transcripts in acute myeloid leukemia. According to recent research from Denmark, "We have developed a real-time quantitative RT-PCR (RQ-PCR) assay for the DEK-CAN fusion transcript, which results from t(6;9) (p23;q34) and is found in about 1% of acute myeloid leukemia (AML) cases." "In diagnostic samples from three acute myeloid leukemia patients, an RQ-PCR assay sensitivity of 1:396-1:3446 was obtained. In a single patient followed closely for 57 weeks," reported M. Ostergaard and coworkers, "an increasing DEK-CAN level was detected 40 days before an early hematological relapse." ...
Source: Cancer Weekly (2004-12-28)
|
